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copy of the spectacle prescription be given
to the patient. However, the law does not
require the release of a contact lens prescription; this is left to the discretion of the
optometrist. You may want to inquire
about your doctor's policy regarding the
contact lens prescription prior to the examination." A majority of the Board believes that such a notice requirement is
necessary to ensure that patients are aware
of this loophole in the law, noting that its
Sacramento office has received numerous
complaints from individuals who were unable to obtain a copy of their contact lens
prescription. Because consumers often assume that they are entitled to receive their
prescriptions, the Board believes that the
proposed notice is necessary to inform
consumers of the law in this area. At this
writing, the Board has not yet published
notice of its intent to adopt this regulation
in the California Regulatory Notice Register.
UCLA Optometry Refresher Course
Update. The first segment of an optometry refresher course primarily designed for
foreign-trained individuals is now completed. Forty-one students participated in
the first part of the course, designed by the
Board and the University of California
and offered through the UCLA Health Sciences Extension Program. [ 12:4 CRLR
114JTwenty of the students recently completed the national written basic science
test (a requirement for licensure); one
passed and eight others achieved scores
just below a passing grade. The clinical
portion of the program began in September and will conclude in April. UCLA
reported that students are very positive
about the class, and that the University
will evaluate the program upon its conclusion.

■ RECENT MEETINGS
At its November 20 meeting, the Board
elected its officers for 1993. Thomas
Nagy, OD, will continue as president; Joseph Dobbs, OD, will serve as vice-president; and John R. Anthony, OD, will serve
as secretary.
Executive Officer Karen Ollinger reported on the Board's enforcement statistics for the period of January through June
1992. During this six-month period, the
Board received 191 complaints regarding
optometrists; a total of 643 complaints
were pending from all prior periods. The
Board closed a total of 64 complaints; of
those, 27 resulted in mediated settlements,
nine were categorized as violations (the
Board issued two citations with a fine and
three warning notices), five were referred
to the Attorney General or other appropriate agency, and 23 were considered un60

actionable. During the six-month period,
the Attorney General's Office filed three
accusations against optometrists; all three
cases resulted in stipulated judgments
with the optometrist receiving suspension
and probation.
The Board also continued its discussion of Business and Professions Code
section 655, which prohibits landlord-tenant relationships, or any other kind of
profit-sharing arrangement, between optometrists and opticians. Previously, the
Board and the Medical Board of
California's Division of Allied Health
Professions had disagreed on the proper
interpretation of section 655. [ 12:4 CRLR
115J However, no additional review is
anticipated at this time, since the Board's
position is consistent with Attorney
General's Opinion No. 80-417 (March 4,
1981 ), and since the Board may establish
further guidelines for optometrists under
its direction, if necessary.

■ FUTURE MEETINGS
May 20--21 in San Diego.

BOARD OF PHARMACY
Executive Officer: Patricia Harris
(916) 445-5014
ursuant to Business and Professions
P
Code section 4000 et seq., the Board
of Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manufacturers, wholesalers and sellers of hypodermic needles. It regulates all sales of
dangerous drugs, controlled substances
and poisons. The Board is authorized to
adopt regulations, which are codified in
Division 17, Title 16 of the California
Code of Regulations (CCR). To enforce its
regulations, the Board employs full-time
inspectors who investigate accusations
and complaints received by the Board.
Investigations may be conducted openly
or covertly as the situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized by
law to suspend or revoke licenses or permits for a variety of reasons, including
professional misconduct and any acts substantially related to the practice of pharmacy.
The Board consists of ten members,
three of whom are public. The remaining
members are pharmacists, five of whom
must be active practitioners. All are appointed for four-year terms.
In late December, Governor Wilson
appointed Darlene Fujimoto to the Board;
Fujimoto is a senior pharmacist and geri-

atric specialist at the University of California at Irvine Medical Center and consultant pharmacist for Clinical Care Pharmacies, Inc. Also in December, Wilson reappointed Janeen McBride to the Board;
McBride is the western region health care
specialist for American Drug Stores, SavOn Drugs.

■ MAJOR PROJECTS
Board to Restructure Enforcement
Unit. At its October 14-15 meeting, the
Board discussed its plans to seek a budget
change proposal (BCP) which would enable it to augment its enforcement program, which has not been expanded in at
least ten years. [ 12:4 CRLR 117-18] According to the Board, the expansion is
necessitated by an increase in the number
of pharmacies and pharmacists, the establishment of new registration programs
such as medical device retailers and pharmacy technicians, and changes in the law
governing the practice of pharmacy; further, the Board expects that the new mandatory patient consultation regulations
which became effective on November I
will alter the delivery of pharmacy care in
California, increasing the visibility of the
profession and the Board's role in protecting the public safety. The Board concedes
that its failure to expand the enforcement
program to meet the number of new programs and licensees has resulted in the
following problems:
-Complaints are open too long; consequently, investigation reports are not filed
in a timely manner, negatively affecting
public safety. Certain complaints that warrant undercover investigation may fail to
be substantiated simply because the inspector cannot devote sufficient time to
perform a thorough investigation or audit
due to oppressive workload demands. As
a result, pharmacists may be cautioned
with an admonition or scheduled for an
appearance before one of the Board's Interim Disciplinary Committees rather than
disciplined through the formal adjudicatory process.
-Drug audits are performed only in
cases where severe shortages are suspected based on the Bureau of Narcotic
Enforcement reports for Schedule II drugs
or purchases of excessively large quantities of certain controlled substances listed
on the Board's wholesaler distribution report. According to the Board, drug audits
of Schedule III and IV drugs are even
more rare, encouraging drug diversion.
For example, the Board suspects that steroids (Schedule III drugs) are being diverted from pharmacies in California for
illegal sale; because the Board is no longer
routinely auditing pharmacies' drug in-
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ventories, it is unable to take proactive
strides to curtail this activity unless investigating a complaint.
-Innovative enforcement issues are
not being expeditiously addressed. For example, in July 199 I, the Board issued a
report on what seemed to be a widespread
pattern of illegal kickbacks between physicians and home health care agencies for
the referral of patients {11:4 CRLR 104;
10:4 CRLR 98]; however, the Board's
heavy workload precluded it from doing
anything but investigate only the most
pressing cases. Also, due to the delay in
availability of Board staff, the FBl's "Operation Goldpill" arrests were delayed at
least 75 days past the nationwide press
conference announcing the undercover investigation involving false Medicare billings and illegal sales of drugs. { 12:4
CRLR 115]
-The Board has not inspected all pharmacies every three years, as is required by
its policy. According to the Board, routine
inspections have been eliminated entirely;
inspections are conducted only when
needed (to issue a new permit, in conjunction with an investigation, or as part of the
terms of a licensee's probation).
-Unless the complainant contacts the
Board, the Board is not able to routinely
provide feedback to those who initiate enforcement cases involving patient injury
during the two and one-half years while
cases are pending in the administrative
disciplinary process; as a result, the Board
appears nonresponsive to consumers
about the more serious complaints in
which accusations are filed.
-Board staff members are required to
spend inordinate amounts of time traveling in order to cover huge territories; for
example, one inspector covers the entire
territory from Orange County south to the
Mexican border and east to Arizona.
-Unlicensed activity by medical device retailers (MDRs) is going unenforced. Despite the program's implementation in July 1991, the Board estimates that a minimum of 200 firms are
working unlicensed as MDRs.
The Board noted that it has no specialized complaint intake staff to receive,
refer, or resolve complaints and inquiries.
Instead, its inspectors handle nearly all
calls and written inquiries regarding enforcement and pharmacy law interpretation, as well as those from consumers with
inquiries or problems with pharmacists,
pharmacies, and pharmaceutical products.
Currently, incoming calls are routed to an
inspector in either the Board's Sacramento
or Los Angeles office. Calls average seven
per workday to each of the Board's thirteen inspectors, and approximately fifteen

per day to each of the two supervising
inspectors who are generally officebound. The Board notes that these are new
inquiries, not follow-up responses regarding investigations and inspections already
in progress with the inspectors.
As a result, the Board is planning to
restructure its enforcement unit by establishing a public inquiry component and
increasing its inspector staff. The Board
plans to redirect the initial intake of telephone and written complaints from the
pharmacy inspectors and instead hire a
consumer service representative and office technician to respond to such inquiries, track complaints and cases, and prepare periodic correspondence to update
those who have contacted the Board. Also,
the Board notes that its inspection staff
must be increased to enable it to investigate complaints expeditiously, conduct
random and periodic inspections of pharmacies, and perform drug audits.
At its October meeting, the Board
agreed to pursue the BCP and to institute
the rulemaking process to increase licensing fees in order to generate funding for
the additional staff; at this writing, notice
of the proposed fee increase has not been
published in the California Regulatory
Notice Register.
Rapid Rise in Drug Prices May Prod
Legislation. Over the past nine years,
prices of prescription drugs have risen at
nearly three times the consumer price
index (CPI). Although they account for
only approximately 5% of total health care
costs, prescription drugs have attracted
consumer attention because insurance
typically does not cover their cost. Congress has mandated that drug manufacturers extend to Medicaid the same discounts
offered to volume buyers such as health
maintenance organizations and hospitals.
U.S. Senator David Pryor (D-Arkansas)
may reintroduce legislation from last session that could deny billions of dollars in
tax credits to those companies whose drug
prices increase at a faster rate than the CPI.
In anticipation of such legislation, some
drug companies have promised to keep
their price increases in line with the CPI.
Patient Consultation Regulations.
On October 14, the Board held a public
hearing on its proposed amendments to
sections 1707. I and 1707 .2, and its proposed adoption of section 1707 .3, Title 16
of the CCR, regarding its patient consultation requirements. According to the
Board, the proposed changes would align
existing California pharmacy regulations
with provisions of the federal Omnibus
Budget Reconciliation Act of 1990
(OBRA 90) which establish patient consultation by pharmacies as a requirement
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for Medicaid-covered patients and specify
required and permissive duties for pharmacists in this regard. {12:4 CRLR 11516} At the hearing, the Board received
extensive testimony on the proposals from
representatives of the County of Orange
Health Care Agency, the California Retailers Association, Kaiser Permanente Medical Care Program, the California Pharmacists Association, and the California Association of Public Hospitals. Following
consideration of the comments received,
the Board adopted the proposed regulatory changes subject to minor modifications. The Board released the revised text
for an additional fifteen-day public comment period; the revisions await review
and approval by the Office of Administrative Law (OAL).
Compounding for Office Use Regulations. On June 22, OALdisapproved the
Board's proposal to adopt new sections
1716.1 and 1716.2, Title 16 of the CCR.
Section 1716.1 would define the quantity
of compounded medication which a pharmacist may furnish to a prescriber for office use under Business and Professions
Code section 4046( c )(I), and section
1716.2 would specify the minimum types
of records that pharmacies must keep
when they furnish compounded medication to prescribers in quantities larger than
required for the prescriber's immediate
office use or when a pharmacy compounds
medication for future furnishing. Among
other things, OAL rejected the sections on
the basis that they failed to meet the clarity
and necessity standards of the Administrative Procedure Act. {12:4 CRLR 116]
At its October meeting, the Board discussed the issues raised by OAL. Executive Officer Patricia Harris explained that
in order to resolve OAL's concerns, staff
made various revisions that needed Board
approval. The two major changes (I) add
language specifying that the term "compounding for prescriber officer use" pertains only to unapproved drugs, and (2)
delete language providing that the term
"compounded medication" also means
repackaging for administration or application to a patient in the prescriber's office
or for dispensing not more than a 72-hour
supply to the prescriber's patient. The
Board approved the amended language; at
this writing, the sections await resubmission to OAL.
Pharmacist-in-Charge Regulations.
The Board's amendment to section
1709.1, Title 16 of the CCR, to allow a
pharmacist to be the pharmacist-in-charge
at two pharmacies if only one of these
pharmacies is open at any given time and
if the pharmacist is the only pharmacist at
each pharmacy, was approved by OAL on
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December 11. [12:4 CRLR 116]
Medical Device Retailers' Locked
Storage Regulations. The Board's
rulemaking file regarding its proposed
adoption of new sections 1748.1 and
1748.2, Title 16 of the CCR, regarding the
proper storage of dangerous devices at
medical device retailer (MDR) retail sites
and the delivery of devices by MDRs to
patients after hours or in emergency situations, was submitted to OAL in mid-December. [12:4 CRLR 117]
FDA Responds to Concerns About
Wholesaler Licenses. In June 1992, OAL
approved the Board's regulatory amendments to section 1780, Title 16 of the
CCR, which change California's requirements for drug wholesalers so that they
meet or exceed the standards of the federal
government under the Prescription Drug
Marketing Act of 1987. [ 12:4 CRLR 116]
Also to comply with federal requirements,
the Board obtained statutory changes to
Business and Professions Code section
4038 to delete the exemption of pharmacies and licensed manufacturers from the
definition of the term "wholesaler,"
through the passage of AB 2743 (Frazee)
(Chapter 1289, Statutes of 1992). [ 12:4
CRLR 117] As a result, pharmacies which
engage in specified activities are subject
to Business and Professions Code section
4084, which provides that no person shall
act as a drug wholesaler unless he/she has
obtained a certificate, license, permit, registration, or exemption from the Board.
In response to its actions, the Board
received inquiries from small independently-owned pharmacies regarding how
the Board will detennine that a phannacy
should be licensed as a wholesaler if that
phannacy engages in the following common practices: (I) sells legend drugs at
wholesale prices to another phannacy to
cover an out-of-stock situation of the buying pharmacy; (2) purchases a volume
deal at a very good price from the manufacturer but cannot use the entire amount
purchased and therefore sells the surplus
to one or more other phannacies at the
"deal" price; and (3) sells vaccines, chemotherapeutic agents, or compounded or
repackaged legend drugs to a prescriber
for office use and/or dispensing to the
ultimate consumer.
In response to these inquiries, Board
Executive Officer Patricia Harris asked
the Food and Drug Administration (FDA)
for clarification as to how the Board
should detennine that a phannacy is engaged in "wholesale" operation and is thus
required to be licensed as a wholesaler. At
its October meeting, the Board reviewed
the FDA's response, which answered each
question as follows:
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(I) Section 205.3(f)(5) of the federal
"Guidelines for State Licensing of Wholesale Prescription Drug Distributors" (Licensing Guidelines) states that wholesale
distribution does not include the sale, purchase, or trade of a drug or an offer to sell,
purchase, or trade a drug for emergency
medical reasons; the term "emergency
medical reasons" includes transfers of prescription drugs by a retail phannacy to
another retail phannacy to alleviate a temporary shortage. Therefore, sales from one
retail pharmacy to another to alleviate a
temporary out-of-stock situation meets
the "emergency medical reasons" criterion of the Licensing Guidelines and does
not require the selling retail pharmacy to
be licensed as a wholesale distributor.
(2) Section 205.3(f) of the Licensing
Guidelines defines "wholesale distribution" as the distribution of prescription
drugs to persons other than a consumer or
patient. The FDA noted that this section
contains eight exceptions, and unless one
of these exceptions is met by the selling
retail pharmacy, the sales are considered
wholesale distribution and the retail pharmacy must be licensed accordingly.
(3) Neither the federal Food, Drug, and
Cosmetic Act nor the federal Licensing
Guidelines address the sale of prescription
drugs by retail pharmacies to licensed
practitioners for office use. According to
the FDA, "[i]n the interests of avoiding
undue interference with nonnal business
practices in the health care field, ... the sale
of minimal quantities of prescription
drugs by a retail pharmacy to licensed
practitioners for office use is not wholesale distribution as contemplated by the
[Prescription Drug Marketing Act]." The
FDA stated its "present position that sales
by a retail phannacy to licensed practitioners of prescription drugs for office use will
not be considered wholesale distribution
requiring state licensing if the total annual
dollar volume of prescription drugs sold
to licensed practitioners does not exceed
five percent of that retail pharmacy's total
annual prescription drug sales."
At the meeting, California Pharmacist
Association (CPhA) representative David
Keast commented that the FD A's response
did not provide any regulatory citation
which provides a basis for the 5% annual
dollar volume; Keast noted that CPhA
would like to work with the Board and
national organizations to persuade the
FDA to take an alternative approach to the
5% annual dollar volume and how it is
measured in order to allow small pharmacies to continue in the way that they practice phannacy.
The Board also discussed that under
the FDA's position, a pharmacy could no

longer purchase volume deals to split between other phannacies, unless the pharmacy has a wholesale license. Board
members noted that small phannacies unable to buy products in large volume will
be adversely affected by the wholesale
licensure requirement. Following discussion, the Board directed staff to inform the
FDA of its concerns regarding the implications of the requirements.

■ LEGISLATION
Future Legislation. The Department
of Consumer Affairs (DCA) has agreed to
carry amendments in its 1993 omnibus bill
regarding the provision of oral consultation to patients by a pharmacist when medications are delivered by mail. [ 12:4
CRLR I 16] The language would state that
any phannacy which ships or mails prescriptions to a resident of California shall
provide telephone service, including a
toll-free number for any long distance
telephone calls, at least six days per week
between the hours of 9:00 a.m. and 6:00
p.m. for patients to consult a pharmacist
who has access to the patient's records.
Written notice of the right to consultation
and the toll-free number for long distance
calls shall be included with or affixed to
each container of drugs dispensed by mail.
Also as part of its omnibus bill, DCA
plans to sponsor legislation that would
give the Board authority to issue interim
orders of license suspension. Although the
Medical Board of California has such authority, the only option presently available
to the Board of Phannacy when a licensee
poses a serious threat to the public safety
is to obtain a temporary restraining order
through the superior court. Proposed section 494 of the Business and Professions
Code would permit the Board to issue an
interim order suspending a license if affidavits in support of the petition show that
the licensee has engaged in, or is about to
engage in, acts or omissions constituting
a violation of a provision of the Business
and Professions Code or has been convicted of a crime substantially related to
the practice of the Iicensee' s profession or
occupation, and that permitting the licensee to continue to engage in practice
would endanger the public health, safety,
or welfare.

■ LITIGATION
At its October 15 meeting, the Board
went into closed session to consult with its
legal counsel regarding Californians for
Sa/e Prescriptions v. California State
Board of Pharmacy, No. BS0l9433, filed
in Los Angeles County Superior Court in
September. The petitioner, a nonprofit organization consisting of approximately
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5,000 California-licensed pharmacists,
sought a writ of mandamus and declaratory and injunctive relief in relation to the
Board's alleged failure to comply with the
Administrative Procedure Act (APA) in
promulgating its pharmacy technician
regulations.
Pursuant to its authority in Business
and Professions Code sections 4008 and
4008.2, the Board attempted in 1989 to
promulgate regulations denominated sections 1717 and 1793-1793.7, Title 16 of
the CCR, which would establish a new
licensing category of individuals who
could perform dispensing-related tasks in
pharmacies under the supervision of licensed pharmacists. [9:4 CRLR 75 J However, over the next two years, OAL disapproved the proposed rules on three occasions, finding that they conflicted with
statutes providing that only licensed pharmacists may compound and dispense
medications. [II: 2 CRLR 97-98; 11: 1
CRLR 83 J The Board then sponsored legislation authorizing it to promulgate the
pharmacy technician regulations. Subsequently, AB 1244 (Polanco) (Chapter 841,
Statutes of 1991) was enacted, authorizing
pharmacy technicians to perform specified tasks. [ 11 :4 CRLR 105-06] The
Board re-proposed its pharmacy technician regulations in December 1991, held
a public hearing on them in January 1992,
adopted them subject to an additional 15day public comment period, and resubmitted its proposed regulations to OAL in
April 1992. OAL again rejected the regulations in June. Shortly after OAL's June
disapproval, petitioner requested that another public hearing be held-pursuant to
Government Code section 11349.4prior to the Board's revision of the regulations and resubmission to OAL. Petitioner
contended that the revisions would have
to be significant to remedy OAL's objections, and that public discussion was
therefore necessary.
On June 17, the Board modified its
regulations and released the modified text
for a 15-day comment period; it did not
schedule another public hearing. Petitioner again requested a public hearing,
this time pursuant to Government Code
section 11346.8(a), and identified several
provisions of the proposed regulations
which were allegedly in conflict with the
Board's enabling statute or were vague
and ambiguous and needed clarification.
The Board resubmitted the regulations to
OAL without conducting an additional
public hearing. On August 12, OAL approved the regulations as amended. Petitioner contended that, because a timely
request was made pursuant to Government Code sections 1 I 346.8(a) and

11349.4, a writ of mandamus is warranted
ordering the Board to hold public hearings
before implementing the regulations.
Petitioner also contended that the regulations must be declared invalid under
Government Code section 11350 on the
basis that they do not comply with the
standards of consistency and clarity required of all regulations by the APA. Specifically, Petitioner contended that:
-Section 1793.2 of the regulations permits pharmacy technicians to perform virtually all the functions of a registered
pharmacist; such a regulation is inconsistent with the legislative intent of Business
and Professions Code section 4008.5.
-Allowing pharmacy technician applicants to qualify for registration based
upon previous experience as a clerk-typist
in a pharmacy is inconsistent with the
legislative intent of Business and Professions Code section 4008.5([), which requires applicants to have experience
equivalent to employment as a pharmacy
technician in assisting in the filling of
prescriptions for an inpatient of a hospital
or for an inpatient of a correctional facility.
-The regulations are inconsistent with
legislative intent in that they permit the
registration of a technician who has not
obtained an associate of arts degree in a
field of study directly related to the duties
performed by a pharmacy technician.
-The regulations are inconsistent with
legislative intent in that they permit registration of a technician who has had less
than the one year of experience required
by Business and Professions Code section
4008.S(f)( l)(D).
-The legislative requirement that a
pharmacy technician be within the pharmacist's view at all times is not clearly or
consistently implemented by the Board's
proposed regulation requiring pharmacists to be fully aware of all activities
involved in the preparation and dispensing
of medications, including the maintenance of appropriate records.
-Language in the regulations requiring
that only a registered pharmacist may
identify, evaluate, and interpret a prescription lacks sufficient clarity to satisfy Government Code section 11349(c).
Finally, Petitioners requested that the
court issue a preliminary injunction enjoining the Board from implementing the
regulations until further order of the court.
On November 2, the matter was heard
by the Los Angeles County Superior
Court; on December 15, the court entered
judgment in the Board's favor. Among
other things, the court held that the Board
followed and complied with the APA in
promulgating and adopting the pharmacy
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technician regulations; the Board was not
legally compelled to hold a second hearing after the rejection of the regulations by
OAL and their revision by the Board, as
each change to the proposed regulations
made by the Board was sufficiently related
to the original text of the regulation that
the public was adequately placed on notice the change could result from the originally proposed regulatory action; nothing
in the regulations is inconsistent with the
language or intent of Business and Professions Code section 4008.5; and the regulations do not lack clarity.
In Huggins v. Longs Drug Stores California, Inc., No. F016033 (Dec. 4, 1992),
the Fifth District Court of Appeal held that
a pharmacist's provision of incorrect dosage amounts for a prescription which the
pharmacist knows or should know will be
administered to an infant by the infant's
parents constitutes negligent action directed at the parent caregivers, which may
allow the caregivers to recover damages
for negligent infliction of emotional distress.
Barbie and Robert Huggins' twomonth-old son Kodee received an overdose of an antibiotic as a result of the
pharmacy's negligence in providing instructions for medication dosage. The parents sued the pharmacy for damages for
negligent infliction of emotional distress;
in the complaint, the parents alleged that
the pharmacy owed them a duty due to
their relationship with the pharmacy.
However, the trial court granted the
pharmacy's motion for summary judgment, concluding that the parents failed to
establish the elements necessary to support a cause of action for negligent infliction of emotional distress; the court held
that the parents could not recover under
the "bystander theory" because there was
"no contemporaneous connection between the negligent act and the injury,"
and "[p]laintiffs cannot recover under a
'direct victim' theory as the duty not to be
negligent is owed to their child."
On appeal, the Fifth District agreed
that the parents may not recover under the
bystander theory, under which the plaintiff's emotional distress results from a direct emotional impact from the sensory
and contemporaneous observance of an
accident, as contrasted with learning of the
accident from others after its occurrence.
The court noted that "the parents did not
suffer emotional distress because of the
overdose until they learned of the overdose from third parties."
However, the court noted that a much
closer question is presented by the parents'
alternative theory-that recovery is permissible under the "direct victim" theory;
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the parents contended that the pharmacist,
by providing the dosage amounts, assumed a duty to them because he knew or
should have known they would have to
administer the prescription to their infant
son and would do so in accordance with
his direction. The court agreed with this
argument, finding that "the action of a
pharmacist, in providing incorrect dosage
under circumstances making it necessary
for a caregiver to administer the medication, would constitute negligence directed
at the caregiver who did so administer."
The court found that "[i]t would be ludicrous to argue that an infant of two months
could either take the medication without
help or could comprehend the misdirection of the dosage. Therefore, under those
circumstances, the negligent giving of instructions to the Huggins is, by its very
nature, directed at the parents, rather than
solely at the infant."
In reviewing the public policy implications of its holding, the court noted
that it discerned "no public policy warranting insulation from liability of a pharmacist who provides instructions for a prescription intended for an infant and who
negligently misstates the dosage, setting
in motion a process which results in death
or serious injury to the child. Rather, we
hold that a parent or close relative who, as
a caregiver, relies upon the directions and
administers the prescription should be allowed recovery under such circumstances."

■ RECENT MEETINGS
At the Board's October 14 meeting,
representatives of Hoag Memorial Hospital requested that the Board issue a hospital pharmacy permit to Hoag's Cancer
Center, which provides outpatient services on its hospital license. In February
1992, Hoag's first such request was denied. Since the Center is not physically
part of the hospital, the Board found that
the drug distribution procedures were not
acceptable insofar as patients at the Center
are considered outpatients and the pharmacy must dispense drugs via a prescription instead of a chart order. At the October meeting, the Board again rejected
Hoag's request, stating that current law
does not authorize the Board to issue a
hospital pharmacy permit unless the pharmacy is physically located in the hospital.
Deputy Attorney General William Marcus
added that unless a statutory change is
made, the Board lacks authority to issue a
pharmacy permit for Hoag's proposed distribution system; Marcus recommended
that Hoag work with other interested parties to pursue such a change.
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■ FUTURE MEETINGS
July 28-29 in Sacramento.
October 6-7 in Sacramento.

BOARD OF
REGISTRATION FOR
PROFESSIONAL
ENGINEERS AND
LAND SURVEYORS
Interim Executive Officer:
Curt Augustine
(916) 263-2222
he Board of Registration for Professional Engineers and Land Surveyors
(PELS) regulates the practice of engineering and land surveying through its administration of the Professional Engineers Act,
sections 6700 through 6799 of the Business and Professions Code, and the Professional Land Surveyors' Act, sections
8700 through 8805 of the Business and
Professions Code. The Board's regulations
are found in Division 5, Title 16 of the
California Code of Regulations (CCR).
The basic functions of the Board are to
conduct examinations, issue certificates,
registrations, and/or licenses, and appropriately channel complaints against registrants/licensees. The Board is additionally
empowered to suspend or revoke registrations/licenses. The Board considers the
proposed decisions of administrative Jaw
judges who hear appeals of applicants who
are denied a registration/license, and those
who have had their registration/license
suspended or revoked for violations.
The Board consists of thirteen members: seven public members, one licensed
land surveyor, four registered Practice Act
engineers and one Title Act engineer.
Eleven of the members are appointed by
the Governor for four-year terms which
expire on a staggered basis. One public
member is appointed by the Speaker of the
Assembly and one by the Senate Rules
Committee.
The Board has established four standing committees and appoints other special
committees as needed. The four standing
committees are Administration, Enforcement, Examination/Qualifications, and
Legislation. The committees function in
an advisory capacity unless specifically
authorized to make binding decisions by
the Board.
Professional engineers are registered
through the three Practice Act categories
of civil, electrical, and mechanical engineering under section 6730 of the Busi-

T

ness and Professions Code. The Title Act
categories of agricultural, chemical, control system, corrosion, fire protection, industrial, manufacturing, metallurgical,
nuclear, petroleum, quality, safety, and
traffic engineering are registered under
section 6732 of the Business and Professions Code.
Structural engineering and geotechnical engineering are authorities linked to
the civil Practice Act and require an additional examination after qualification as a
civil engineer.

■ MAJOR PROJECTS
PELS to Interview Prospective Executive Officers. PELS is continuing its
efforts to fill the Executive Officer (EO)
position vacated by Darlene Stroup in August 1992. [12:4 CRLR 118] At PELS'
November 20 meeting, Interim EO Curt
Augustine reported that the Board had received 178 applications for the position.
At this writing, the semifinal round of
interviews for the position is scheduled to
be held in Sacramento on January 14-15,
with final interviews taking place in Los
Angeles on January 28.
PELS Adopts Policy Regarding Disadvantaged Business Enterprises. At its
November 20 meeting, the Board reviewed an opinion of the Department of
Consumer Affairs' (DCA) Legal Office
regarding whether the Professional Engineers Act or Professional Land Surveyors'
Act permits an unregistered person who is
a part owner of a professional engineering
or land surveying business to qualify the
business as a minority-owned, womenowned, or disadvantaged business enterprise (DBE) in order to obtain state contracts. DCA previously concluded that an
unregistered person may be a part owner
or manager of a professional business,
provided (1) there is a professional engineer as an owner, part owner, or officer in
charge of the engineering practice of the
business; (2) all engineering work is prepared under the responsible charge of a
professional engineer in the appropriate
branch of professional engineering; and
(3) the unregistered person limits his/her
managerial role to aspects of the business
which do not involve the practice of professional engineering.
However, recently-enacted AB 486
(Polanco) (Chapter 1329, Statutes of
1992) creates uniform certification criteria for DBE firms hired by state agencies
and defines the requisite control which
must be exercised by a disadvantaged
owner to qualify the firm as a DBE; the
new Jaw cites Part 23, Title 49 of the Code
of Federal Regulations as the source of the
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